CaaS Capital Management logo

CaaS Capital Management

North America, New York, United States, New York

Description

CaaS Capital Management is investing across all regions, industries, and capital structures.

Investor Profile

CaaS Capital Management has made 15 investments, with 1 in the past 12 months and 7% as lead.

Stage Focus

  • Series B (33%)
  • Series C (33%)
  • Post Ipo Equity (20%)
  • Private Equity (7%)
  • Series D (7%)

Country Focus

  • United States (87%)
  • Germany (7%)
  • United Kingdom (7%)

Industry Focus

  • Biotechnology
  • Biopharma
  • Therapeutics
  • Health Care
  • Life Science
  • Pharmaceutical
  • Genetics
  • Oncology
  • Medical
  • Information Technology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does CaaS Capital Management frequently co-invest with?

Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 4
Casdin Capital
North America, New York, United States, New York
Co-Investments: 3
Avidity Partners
North America, Texas, United States, Dallas
Co-Investments: 3
RTW Investments
North America, New York, United States, New York
Co-Investments: 4
Bain Capital Life Sciences
North America, Massachusetts, United States, Boston
Co-Investments: 3
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 4
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 3
Soleus Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 3
Sixty Degree Capital
North America, Ontario, Canada, Toronto
Co-Investments: 3
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 3

What are some of recent deals done by CaaS Capital Management?

Umoja Biopharma

Seattle, Washington, United States

Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.

BiopharmaBiotechnologyDeveloper Platform
Series CJan 14, 2025
Amount Raised: $100,000,000
Solid Biosciences

Marlborough, Massachusetts, United States

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

BiotechnologyGeneticsHealth CareMedical
Post Ipo EquitySep 30, 2022
Amount Raised: $75,000,000
Ventyx Biosciences

Encinitas, California, United States

Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.

BiopharmaBiotechnology
Post Ipo EquitySep 19, 2022
Amount Raised: $176,600,000
2seventy bio

Cambridge, Massachusetts, United States

2seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies.

BiotechnologyGeneticsHealth CareOncologyTherapeutics
Post Ipo EquityMar 16, 2022
Amount Raised: $170,000,000
HotSpot Therapeutics

Boston, Massachusetts, United States

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.

BiopharmaBiotechnologyHealth CareLife ScienceTherapeutics
Series CNov 29, 2021
Amount Raised: $100,000,000
T-knife

Berlin, Berlin, Germany

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.

Biotechnology
Series BAug 2, 2021
Amount Raised: $110,000,000
Artios Pharma

Cambridge, Cambridgeshire, United Kingdom

Artios Pharma is a independent DNA Damage Response company with a strong pipeline of novel cancer therapies.

BiopharmaBiotechnologyMedical Device
Series CJul 27, 2021
Amount Raised: $152,701,427
Turnstone Biologics

La Jolla, California, United States

Turnstone Biologics is a privately-held clinical stage biotech company.

BiotechnologyInnovation ManagementTherapeutics
Series DJul 14, 2021
Amount Raised: $79,999,979
Umoja Biopharma

Seattle, Washington, United States

Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.

BiopharmaBiotechnologyDeveloper PlatformInformation Technology
Series BJun 15, 2021
Amount Raised: $210,000,000
Arcellx

Gaithersburg, Maryland, United States

Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.

BiopharmaBiotechnologyHealth CareLife SciencePharmaceutical
Series CApr 13, 2021
Amount Raised: $115,000,000